Skip to main content

Table 2 Treatment related adverse events

From: Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

 

All grades

Grades III-IV

 

N

%

N

%

Leukopenia

12

25.1

-

-

Neutropenia

11

23.0

3

6.3

Anemia

38

79.1

-

-

Thrombocytopenia

18

37.5

-

-

Nausea

11

23.0

2

4.2

Vomiting

9

18.8

2

4.2

Diarrhea

13

27.2

3

6.3

Mucositis

3

6.3

-

-

Dysgefsia

1

2.1

  

Constipation

9

18.8

1

2.1

Abdominal pain

4

8.3

  

Non cardiac chest pain

1

2.1

  

Neurotoxicity

18

37.5

1

2.1

Seizures

1

2.1

  

Headache

3

6.3

  

Allergic reaction

1

2.1

1

-

Asthenia

264

54.2

2

4.2

Anorexia

5

10.4

  

Cutaneous toxicity

1

2.1

-

-

Fever

2

4.2

-

-

Hemorrhage

1

2.1

-

-

Hypertension

3

6.3

1

2.1

.1

Hand foot syndrome

1

2.1

  
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us